Abstract

Acute lymphoblastic leukemia (ALL) is a heterogeneous disease affected by many factors,including age,immunologic subtype,and clinical,genetic and molecular features,Improved tools can identify patients in remission based on morphology but those with active disease based on molecular biology or immunophenotype (minimal residual disease).B-cell antigen panels,clone-specific immunoglobulins,or T-cell receptor rearrangements is used to detect positivity at thresholds at least.There are 13 ALL clinical related abstracts (poster) in the 19th European Hematology Association annual congress which reflected recent progress of research ALL. Key words: Leukemia, lymphoblastic, acute; European Hematology Association annual congress

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.